The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Off-Year Revision Debate to Follow Honebuto Policy: MHLW Bureau Chief
July 29, 2024
- MHLW Plans Disposal of COVID-19 Antibody Meds in Government Stock
July 26, 2024
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
- Health Minister Hopes to Tap US Insights to Foster Japan Ecosystem
July 24, 2024
- MHLW Seeks Input to Gird for Summer Outbreaks, FPMAJ Ready to Ask for Ramp-Up
July 23, 2024
- Japan’s Fall-Winter COVID Vaccinations Likely to Start from October
July 23, 2024
- MHLW Panel to Review Takeda’s Fruzaqla on Aug. 2; Truvada, Keytruda, Prevenar 20 on Roster Too
July 22, 2024
- MHLW Sets Exceptions to All-Case PMS through Revised Q&A
July 22, 2024
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Lilly’s Alzheimer’s Med Up for Health Ministry Panel Review on August 1
July 19, 2024
- MHLW Pharma Management Director Hints at Addressing “Zero” Premium Issue
July 19, 2024
- Chuikyo OKs Plan for Drug Price Survey in FY2024
July 18, 2024
- Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo
July 18, 2024
- Label Revisions Ordered for Opdivo, Yervoy, Duvroq, and More
July 18, 2024
- LDP Lawmakers Call for Expanded Budget for Pharma Innovation, Stable Supplies
July 18, 2024
- MHLW Clarifies Criteria for “Medical Necessity” of LLPs before Elective Care Rollout
July 17, 2024
- Pharma Innovation, Supply Raised as Key Topics for FY2025 Budget: LDP Confab
July 10, 2024
- Japan Wants to Spur Regulatory Use of RWD, but Still Puts Weight on RCTs
July 10, 2024
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…